SPY416.07+3.90 0.95%
DIA341.30+3.18 0.94%
IXIC13,950.22+163.95 1.19%

UPDATE: Solid Biosciences Says Interim Data From Six Patients 'provide evidence of a potential benefit of SGT-001 in functional endpoints'; Says 'six patients previously dosed showed no new drug-related safety findings'

- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tests (PFTs), and

· 03/15/2021 16:18